By using an assay system based on a human hepatoblastoma cell line (HB611) that continuously synthesizes hepatitis B virus DNA, the following compounds were found to inhibit hepatitis B virus DNA synthesis at concentrations that were significantly lower than their minimum cytotoxic concentrations: 9-(2-phosphonylmethoxyethyl)-2,6-dianiinopurine (PMEDAP), (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine, 9-(phosphonylmethoxyethyl)adenine, 2',3'-dideoxy-2',3'-didehydrocytidine, and 2',3'-dideoxycytidine. The most potent compound was PMEDAP (50% effective concentration, 0.02 pg/ml). The Recently, a number of assay systems have been described which seem suitable for evaluation of the inhibitory effects of antiviral compounds against hepadnaviruses, including HBV and duck hepatitis B virus (DHBV) (5, 9, 11, 13, 15). DHBV is able to propagate in primary duck hepatocytes in vitro (12). Selective inhibition of the synthesis of DHBV DNA and core antigen in primary duck hepatocytes can be used as a marker for anti-DHBV activity. Using this assay system, we examined a variety of purine and pyrimidine nucleoside analogs for their inhibitory effects on DHBV replication (15).
Hepatitis B virus (HBV) is the causative agent of both the acute and chronic forms of hepatitis. More than 200 million people worldwide are estimated to be chronic carriers of HBV. Efficient anti-HBV drugs have been long awaited. The major problem in the development of such drugs is that an adequate in vitro assay system is not available for the evaluation of potential anti-HBV drugs, because HBV does not readily replicate in culture cells.
Recently, a number of assay systems have been described which seem suitable for evaluation of the inhibitory effects of antiviral compounds against hepadnaviruses, including HBV and duck hepatitis B virus (DHBV) (5, 9, 11, 13, 15) . DHBV is able to propagate in primary duck hepatocytes in vitro (12) . Selective inhibition of the synthesis of DHBV DNA and core antigen in primary duck hepatocytes can be used as a marker for anti-DHBV activity. Using this assay system, we examined a variety of purine and pyrimidine nucleoside analogs for their inhibitory effects on DHBV replication (15) .
Ueda et al. (13) have recently described a human hepatoblastoma cell line (HB611) that contains an integrated HBV genome and that accumulates a significant amount of HBV DNA replicative intermediates. Some of these DNA molecules are packed and released as Dane particles into the cell culture medium. Selective inhibition of the synthesis of these replicative intermediates could serve as a marker for anti-HBV activity. Using the HB611 cell line, we examined the inhibitory effects of selected antiviral compounds on HBV DNA synthesis. The compounds which we evaluated for their inhibitory effect on HBV DNA synthesis were previously examined for their inhibitory effects on DHBV DNA and core antigen synthesis in primary duck hepatocytes (15) .
The compounds fell into two categories: phosphonylmethoxyalkylpurines and -pyrimidines and 2',3'-dideoxynucleoside analogs. Their origins were as follows. The phosphonylmethoxyalkylpurines and -pyrimidines (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA], (S) - S (see Fig. 1 legend) was checked on the filter by comparison with the results of autoradiograpy. Then, the filter was cut off to four pieces of I, Dl, D2, and S. Each piece was analyzed for radioactivity in a liquid scintillation counter. The 50% effective concentration (EC50) was defined as the concentration required to inhibit HBV DNA synthesis by 50%. The EC50s were calculated from the (Dl + D2 + S)/I value of radioactivity (Fig. 1) .
Cytotoxicity measurements were based on the inhibition of deoxythymidine (dThd) incorporation into HB611 cells. The cells were seeded in a 24-well tissue culture tray at 106 cells per well in 1 ml of growth medium containing various concentrations of the test compounds and 0.5 ,Ci of [6-3H]dThd. After 24 h of incubation, the cells were harvested and washed three times with phosphate-buffered saline. The acid-insoluble fractions were analyzed for radioactivity in a liquid scintillation counter as described previously (10) . The concentration of test compound which inhibited the incorporation of [6-3H] dThd into the acid-insoluble fraction of hepatocytes to 50% of the control value was defined as the 50% cytotoxic concentration (CC50). Cytotoxicity assays were also based on the inhibition of cell growth. A compound that specifically interfered with HBV DNA synthesis may be expected to block the synthesis of the viral replicative intermediates (bands Dl, D2, and S) but not the synthesis of the integrated viral DNA (band I) (Fig. 1) . As shown in Table 1 and Fig. 2, (S Of the 2',3'-dideoxynucleoside analogs that were investigated for their inhibitory effects on HBV DNA synthesis, DDC was the most potent (EC50, 0.76 ,g/ml) and the most selective (Table 1) . D4C showed moderate selectivity in inhibiting HBV DNA synthesis, whereas D4T was virtually inactive. Ara-A, an agent that has been used clinically in the treatment of HBV infection, did not show selectivity (selectivity index, <1) as an anti-HBV agent in vitro.
The phosphonylmethoxyalkylpurines and -pyrimidines [i.e., (S)-HPMPA, PMEA, and PMEDAP] are inhibitory to a broad spectrum of DNA viruses, including adenoviruses, poxviruses, iridoviruses (African swine fever virus), and herpesviruses (i.e., herpes simplex virus types 1 and 2, cytomegalovirus, varicella-zoster virus, and Epstein-Barr virus) (1, 4, 6, 14) . These compounds inhibited HBV DNA synthesis in HB611 cells at low concentrations (0.02 to 0.35 ,ug/ml) and had high selectivity indices in vitro. PMEDAP is the most potent and most selective inhibitor of HBV DNA synthesis that has been reported so far. It is noteworthy that, in addition to their anti-HBV activities, PMEA and PMEDAP also exhibited marked inhibitory activities against human immunodeficiency virus (1, 4, 6) . Of all the compounds tested, PMEDAP and (S)-HPMPA also proved to be the most selective in inhibiting the replication of DHBV in primary duck hepatocytes (15) . Thus, the antiviral activity spectrum of the phosphonylmethoxyalkyl derivatives not only encompassed adeno-, pox-, irido-, herpes-, and retroviruses but it also extended to the hepadnaviruses. The mechanism of antiviral action of the phosphonylmethoxyalkylpurines and -pyrimidines was not defined. (S)-HPMPA was, as such, taken up by the cells and subsequently converted to its monophosphoryl and diphosphoryl derivatives by cellular enzymes. (S)-HPMPA inhibits the synthesis of herpesvirus DNA at concentrations which are several orders of magnitude lower than the concentration required to inhibit cellular DNA synthesis (1, 6, 14) . Thus, (S)-HPMPA discriminates between viral and cellular DNA synthesis, and this may apparently contribute to its selective inhibitory activity against herpes simplex virus, EpsteinBarr virus, and African swine fever virus, as well as other viruses. HPMPA, PMEA, and PMEDAP inhibited not only the Dl and D2 bands but also the S band (Fig. 1) . This means that HPMPA, PMEA, and PMEDAP may inhibit both the DNA polymerase and reverse transcriptase activities that are specified by HBV. Further investigations are warranted to determine the interaction of the putative active forms (diphosphoryl derivatives) of HPMPA, PMEA, and PMEDAP with the HBV-associated reverse transcriptase and DNA polymerase.
The 2',3'-dideoxynucleosides (i.e., DDC, D4T, and D4C) are well-known for their selective inhibitory effects on human immunodeficiency virus replication (2, 3, 5, 7, 8, 11, 13) . Some 2',3'-dideoxynucleosides, i.e., 2',3'-dideoxyguanosine and 2',3'-dideoxy-2,6-diaminopurineriboside, have also been reported to inhibit DHBV replication in primary duck hepatocytes (5, 11) . Also, Ueda et al. (13) reported that DDC inhibits HBV DNA synthesis at a concentration of 1.6 ,uM. Our own data have confirmed that DDC is indeed a potent and selective inhibitor of HBV DNA synthesis. DDA was also active, but less so than DDC. D4C and D4T represent two other dideoxynucleoside analogs which are selective inhibitors of human immunodeficiency virus replication (2, 3, 7, 8) . Of these two compounds, D4C was effective in inhibiting HBV DNA synthesis. whereas D4T was not.
In conclusion, several antiviral compounds which were previously shown to inhibit the replication of DNA viruses, retroviruses, or both were examined for their inhibitory effects on HBV DNA synthesis in HB611 cells. The most potent and selective inhibitors of HBV DNA synthesis were PMEDAP, PMEA, (S)-HPMPA, DDC, and D4C. These compounds appear to be worth pursuing as candidate drugs for the chemotherapy of HBV infections.
